NPPA's Gazette notification of 17 October 2026 caps the trade margin on 137 non-scheduled anti-cancer drugs at 30% of MRP under Paragraph 19 of the DPCO, 2013; revised prices apply from 9 November 2026.
MRPs are expected to fall by up to 70%; the list was recommended by an Expert Committee under the DGHS and will be updated periodically.
It extends NPPA's 2019 pilot, which capped margins on 42 anti-cancer drugs and cut the MRP of 526 brands by up to 90%.
GS Paper 2 > Governance > Health > Drug Pricing
The gap between the price at which a manufacturer first sells a drug and its MRP, which distributors and retailers keep.
A drug outside the DPCO's First Schedule (the NLEM list), so it has no ceiling price; only Paragraph 19 or the annual increase limit restrains it.